Search clinical trials for: P-IL-2 plus Anti-PD-1 Monoclonal Antibody

Total 995 results

Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

Stage II Breast Cancer AJCC v6 and v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Breast Adenocarcinoma

United States
Capital Medical University

Completed

Hyperthermia Combined With Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases

Cancer | Metastatic Cancer | Abdominal Cancer | Pelvic Cancer | Liver Metastases | Peritoneal Metastases

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery

Cholangiocarcinoma | Liver and Intrahepatic Bile Duct Carcinoma | Unresectable Gallbladder Carcinoma | Stage III Gallbladder Cancer AJCC v7 | Stage IIIA Gallbladder Cancer AJCC v7 | Stage IIIB Gallbladder Cancer AJCC v7 | Stage IV Gallbladder Cancer AJCC v7 | Stage IVA Gallbladder Cancer AJCC v7 | Stage... and other conditions

United States
National Institute of Allergy and Infectious Diseases...
Inner-City Asthma Consortium

Completed

Inner-City Anti-IgE Therapy for Asthma (ICATA)

Asthma

United States
Emory University
National Cancer Institute (NCI); Novartis; National Institutes of Health (NIH); EUSA Pharma, Inc...

Completed

Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer

Recurrent Colorectal Carcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Colon Cancer AJCC v8 and other conditions

United States
Zhejiang Cancer Hospital

Not yet recruiting

HIPEC Combined With Camrelizumab, Paclitaxel and S-1 for Conversion Therapy in Patients With Advanced Gastric Cancer With Peritoneal Metastasis

Gastric Cancer, HIPEC, Anti-PD-1 Antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery

China
West China Hospital

Recruiting

Combination of Sintilimab and Stereotactic Body Radiotherapy in Advanced Metastatic HCC

Immunotherapy | SBRT | Stage IV HCC

China
Shanghai Zhongshan Hospital

Unknown

SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma (SHR-1210)

Hepatocellular Carcinoma

China
Shanghai Zhongshan Hospital

Unknown

SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery

Hepatocellular Carcinoma

China
Peregrine Pharmaceuticals

Completed

Radiolabeled Monoclonal Antibody in Treating Patients With Glioblastoma Multiforme or Anaplastic Astrocytoma

Brain and Central Nervous System Tumors

United States
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Neo-Sequence 2：NCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGC

Gastric Cancer | Diffuse Type Carcinoma

China
University of California, Davis

Unknown

Monoclonal Antibody Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma

Lymphoma

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) for Recurrent, Metastatic, or Unresectable HER2-Positive Salivary Gland Cancer

Recurrent Salivary Gland Carcinoma | Stage III Major Salivary Gland Cancer AJCC v8 | Stage IV Major Salivary Gland Cancer AJCC v8 | Metastatic Salivary Gland Carcinoma | Unresectable Salivary Gland Carcinoma

United States
St George's, University of London

Unknown

Study of Single IV Administration of P2G12 (FuturePharma)

HIV Infection

United Kingdom
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Producing Advanced or Metastatic Cancers

Metastatic Cancer | Advanced Cancer

United States
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Suspended

A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC

Triple Negative Breast Cancer

China
Sixth Affiliated Hospital, Sun Yat-sen University

Recruiting

mFOLFOX6+Bevacizumab+PD-1 Monoclonal Antibody in Local Advanced MSS CRC (BASKETⅡ)

Colorectal Cancer | Immunotherapy

China
Case Comprehensive Cancer Center

Terminated

Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal Cancer

Rectal Cancer | Colon Cancer

United States
Shanghai Junshi Bioscience Co., Ltd.

Completed

JS016 (Anti-SARS-CoV-2 Monoclonal Antibody)With Mild and Moderate COVID-19 or SARS-CoV-2 Asymptomatic Infection Subects

COVID-19

China
Jason J. Luke, MD
Bristol-Myers Squibb

Recruiting

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors

Melanoma | Carcinoma, Renal Cell | Unresectable Solid Tumors

United States
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma

Recurrent Neuroblastoma | Disseminated Neuroblastoma | Regional Neuroblastoma

United States
Hengenix Biotech Inc
Sanyou Biopharmaceuticals(Shanghai)Co., Ltd; Shanghai ZJ Bio-Tech Co., Ltd

Withdrawn

Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers

COVID 19
St. Jude Children's Research Hospital
CURE Childhood Cancer, Inc.

Completed

Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma

Neuroblastoma

United States
Bassett Healthcare
PriCara, Unit of Ortho-McNeil, Inc.

Completed

Comparative Effects of Azithromycin, Telithromycin and Levofloxacin on Drug Metabolizing Enzymes

Healthy
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.

Locally Advanced Unresectable Esophageal Squamous Carcinoma

China
Robert L. Ferris, MD, PhD
Bristol-Myers Squibb

Recruiting

Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma (HNSCC)

United States
Waterstone Hanxbio Pty Ltd

Recruiting

Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma

Relapsed/Refractory Lymphoma

China
Sun Yat-sen University

Recruiting

Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma

Recurrent Nasopharyngeal Carcinoma

China
National Cancer Institute (NCI)

Completed

Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia

B-cell Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States
Chinese PLA General Hospital

Recruiting

Decitabine and Anti-PD-1 in R/R DLBCL

Diffuse Large B Cell Lymphoma | Central Nervous System Lymphoma | Extranodal Extension | Relapse/Recurrence

China
CSL Behring

Completed

Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis

Hidradenitis Suppurativa | Palmoplantar Pustulosis

Denmark, Australia, Germany
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Active, not recruiting

Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer

Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer

United States
M.D. Anderson Cancer Center

Recruiting

Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma

Chordoma | Metastatic Chordoma | Unresectable Chordoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study

Melanoma | Metastatic Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Recurrent Metastatic Melanoma

United States
Fudan University

Recruiting

Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer (Miracle-G)

Adenocarcinoma | Metastatic Cancer | Metastatic Gastric Cancer | Gastroesophageal Junction Adenocarcinoma | Oligometastatic Disease | Stomach Neoplasm | Adenocarcinoma of the Stomach | Gastroesophageal-junction Cancer | Metastatic Adenocarcinoma

China
University of California, Irvine
National Cancer Institute (NCI); National Institutes of Health (NIH)

Completed

Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting

Breast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm

United States
Beijing Friendship Hospital

Not yet recruiting

L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH

Lymphoma | Hemophagocytic Lymphohistiocytosis | PD-1 Antibody | Epstein-Barr Virus

China
Beijing Friendship Hospital

Not yet recruiting

L-DEP/DEP Regimen and PD-1 Antibody as a Treatment for Relapse/Refractory EBV-HLH

Hemophagocytic Lymphohistiocytosis

China
Sun Yat-sen University
Guangzhou No.12 People's Hospital; Kaiping Central Hospital

Withdrawn

TACE Plus PD-1 Antibody vs TACE Alone for Unresectable HCC

Hepatocellular Carcinoma

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Metastatic Breast Carcinoma | Locally Advanced Breast Carcinoma | Breast Inflammatory Carcinoma

United States
Genzyme, a Sanofi Company
Cambridge Antibody Technology

Completed

Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis

Systemic Sclerosis | Scleroderma

United States
Shanghai Zhongshan Hospital

Recruiting

Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCC

Hepatocellular Carcinoma

China
Heidelberg University
Verein für Krebsforschung, Arlesheim, Swizzerland; Weleda AG, D-73525 Schwäbisch...

Completed

Mistletoe Extract in Early or Advanced Breast Cancer, A Feasibility Study

Metastatic Breast Cancer

Germany
Sun Yat-sen University

Active, not recruiting

Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in pMMR/MSS CRLM Patients

Colorectal Cancer Metastatic

China
Beijing Tongren Hospital

Unknown

Lenalidomide and Sintilimab for Relapsed/Refractory NK/T-cell Lymphoma

NK/T Cell Lymphoma Nos

China
National Cancer Institute (NCI)

Active, not recruiting

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

Recurrent Childhood Ependymoma | Advanced Malignant Solid Neoplasm | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent Non-Hodgkin... and other conditions

United States, Puerto Rico
Southwest Oncology Group
National Cancer Institute (NCI); Roche-Genentech

Completed

S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer

Colorectal Cancer

United States
Washington University School of Medicine

Withdrawn

Lapatinib With Trastuzumab in Treating Patients With HER2-Negative/HER2 Mutant Metastatic Breast Cancer

Breast Neoplasms

Search clinical trials for: P-IL-2 plus Anti-PD-1 Monoclonal Antibody

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations